Potential Anticancer Agents Characterized from Selected Tropical Plants

Higher plants are well known for their value in affording clinically useful anticancer agents, with such compounds acting against cancer cells by a range of mechanisms of action. There remains a strong interest in the discovery and development of plant secondary metabolites as additional cancer chemotherapeutic lead compounds. In the present review, progress on the discovery of plant-derived compounds of the biflavonoid, lignan, sesquiterpene, steroid, and xanthone structural types is presented. Several potential anticancer leads of these types have been characterized from tropical plants collected in three countries as part of our ongoing collaborative multi-institutional project. Preliminary structure-activity relationships and work on in vivo testing and cellular mechanisms of action are also discussed. In addition, the relevant work reported by other groups on the same compound classes is included herein.

Anti-CD22-conjugated CdTe QDs co-loaded with doxorubicin and gambogic acid: a novel platform for lymphoma treatment

DOX/GA–CdTe–CD22 can precisely target lymphoma and deliver DOX and GA to lymphoma cells to improve their therapeutic effects.

Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers

Simultaneous prolonged delivery of therapeutic gene, hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive LipoNiosome has been considered as a novel and promising method in order to treatment multi-drug resistant cancer.